MADRIGAL PHARMACEUTICA

328,19

29-ноября-24 12:45:00

15 мин. задержка

Акции

-3,26

-0,98%

Сегодняшний диапазон

323,50 - 331,15

ISIN

N/A

Источник

NASDAQ

Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results

09 май 2023 07:00:02 Источник Nasdaq GlobeNewswire
Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial

18 апр 2023 07:00:01 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results

23 фев 2023 07:00:02 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

08 фев 2023 07:00:01 Источник Nasdaq GlobeNewswire
Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis

06 янв 2023 07:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program

21 дек 2022 15:15:14 Источник Nasdaq GlobeNewswire
Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis

19 дек 2022 06:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NASH Study of Resmetirom on Monday, December 19th

18 дек 2022 15:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Provides an Overview of Upcoming Resmetirom Data Presentations and Reports 2022 Third Quarter Financial Results

03 ноя 2022 07:00:03 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

07 сен 2022 07:00:04 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis

31 авг 2022 07:00:02 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results

04 авг 2022 07:00:08 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™

25 июн 2022 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Supports International NASH Day on June 9

06 июн 2022 07:00:01 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

02 июн 2022 07:00:03 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

17 май 2022 07:00:01 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results

09 май 2022 05:30:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9

28 апр 2022 07:00:02 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference

09 мар 2022 15:30:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results

24 фев 2022 07:00:02 Источник Nasdaq GlobeNewswire

<<
<
1
2
3
4
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.